Nurix Therapeutics (NRIX) News Today $11.51 -0.10 (-0.84%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Consensus Target Price from AnalystsApril 24 at 1:29 AM | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Trading 6.4% Higher - Here's What HappenedNurix Therapeutics (NASDAQ:NRIX) Trading 6.4% Higher - Here's What HappenedApril 23 at 1:24 PM | marketbeat.comJump Financial LLC Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Jump Financial LLC bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 74,619 shares of the company's stock, valuedApril 22 at 4:25 AM | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and sixteen haApril 22 at 2:33 AM | marketbeat.comWasatch Advisors LP Has $11.29 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Wasatch Advisors LP lessened its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 15.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 599,401 shares of the coApril 19, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC grew its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,585,127 shares of the company's stock aApril 19, 2025 | marketbeat.comNurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory ConditionsApril 18, 2025 | finanznachrichten.deNurix Therapeutics (NASDAQ:NRIX) Shares Gap Down - What's Next?Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down - Time to Sell?April 17, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Affinity Asset Advisors LLCAffinity Asset Advisors LLC boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 940,083 shares of the company's stock after buying anApril 17, 2025 | marketbeat.comNurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory ConditionsApril 17, 2025 | globenewswire.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Fmr LLCFmr LLC lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 1,711.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,634,231 shares of the company's stock after purchasing an additiApril 15, 2025 | marketbeat.comTrexquant Investment LP Reduces Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Trexquant Investment LP lowered its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 85.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,527 shares of the company's stock after selApril 15, 2025 | marketbeat.comLeerink Partnrs Has Optimistic Outlook of NRIX Q2 EarningsNurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Stock analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of Nurix Therapeutics in a research note issued to investors on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post eApril 13, 2025 | marketbeat.comNorges Bank Buys New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Norges Bank bought a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 318,800 shares of the company's stock, valuApril 12, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Lifted by Vanguard Group Inc.Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 8.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,345,266 shares of the company's stock after buying an additiApril 12, 2025 | marketbeat.comNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $25.00 at Wells Fargo & CompanyWells Fargo & Company cut their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday.April 11, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $35.00 at Stifel NicolausStifel Nicolaus reduced their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday.April 11, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $27.00 by Analysts at Needham & Company LLCNeedham & Company LLC reduced their price target on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday.April 11, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Posts Earnings Results, Beats Expectations By $0.05 EPSNurix Therapeutics (NASDAQ:NRIX - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The business had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same quarter in the prior year, the company posted ($0.76) EPS.April 11, 2025 | marketbeat.comExodusPoint Capital Management LP Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)ExodusPoint Capital Management LP raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 147.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,662 shares of the company'sApril 11, 2025 | marketbeat.comNurix Therapeutics price target lowered to $25 from $32 at Wells FargoApril 10, 2025 | markets.businessinsider.comNurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateApril 10, 2025 | finanznachrichten.deNurix Therapeutics price target lowered to $32 from $35 at OppenheimerApril 10, 2025 | markets.businessinsider.comNurix Therapeutics (NRIX) Receives a New Rating from RBC CapitalApril 10, 2025 | markets.businessinsider.comNurix Therapeutics (NASDAQ:NRIX) Sets New 1-Year Low - Time to Sell?Nurix Therapeutics (NASDAQ:NRIX) Hits New 12-Month Low - Should You Sell?April 9, 2025 | marketbeat.comPolymer Capital Management HK LTD Acquires Shares of 50,098 Nurix Therapeutics, Inc. (NASDAQ:NRIX)Polymer Capital Management HK LTD bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 50,098 shares of the company's stock, valued at approximately $944,000. PolApril 9, 2025 | marketbeat.comNurix Therapeutics reports Q1 EPS (67c), consensus (76c)April 9, 2025 | markets.businessinsider.comNurix Therapeutics Q1 2025 Financial HighlightsApril 9, 2025 | tipranks.comNurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateApril 8, 2025 | globenewswire.comNurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateApril 8, 2025 | globenewswire.comSpringhill Fund Asset Management HK Co Ltd Makes New $3.02 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 160,500 shares of the company's stock, valApril 8, 2025 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for NRIXNurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - HC Wainwright boosted their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, April 2nd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.60) fApril 8, 2025 | marketbeat.comWellington Management Group LLP Buys 104,500 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)Wellington Management Group LLP increased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,586,605 shareApril 7, 2025 | marketbeat.comBryce Point Capital LLC Acquires Shares of 28,564 Nurix Therapeutics, Inc. (NASDAQ:NRIX)Bryce Point Capital LLC bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 28,564 shares of the company's stock, valued at approximately $538,000. A number of other hedgApril 6, 2025 | marketbeat.comCinctive Capital Management LP Grows Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Cinctive Capital Management LP increased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 51.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 158,972 shares of the company's stock after acquiring an additional 53,744 shares during thApril 5, 2025 | marketbeat.comLeerink Partners Sticks to Its Hold Rating for Nurix Therapeutics (NRIX)April 5, 2025 | markets.businessinsider.comRaymond James Financial Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Raymond James Financial Inc. bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 54,453 shares of the company'April 5, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Shares Up 4.2% - What's Next?Nurix Therapeutics (NASDAQ:NRIX) Shares Up 4.2% - Here's What HappenedApril 4, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a report on Wednesday.April 4, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Shares Down 8.9% - Should You Sell?Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 8.9% - Here's What HappenedApril 3, 2025 | marketbeat.comNurix Therapeutics (NRIX) Projected to Post Earnings on WednesdayNurix Therapeutics (NASDAQ:NRIX) will be releasing earnings before the market opens on Wednesday, April 9, Financial Modeling Prep reports.April 3, 2025 | marketbeat.com5NRIX : Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 AnalystsApril 2, 2025 | benzinga.comNurix Therapeutics in Expanded Collaboration with SanofiApril 2, 2025 | marketwatch.comNurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune DiseasesApril 2, 2025 | globenewswire.comNEOS Investment Management LLC Acquires Shares of 22,557 Nurix Therapeutics, Inc. (NASDAQ:NRIX)NEOS Investment Management LLC acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,557 shares of the company's stock,April 2, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Hits New 12-Month Low - What's Next?Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year Low - Here's WhyApril 1, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been given an average rating of "Moderate Buy" by the eighteen ratings firms that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and fifteen have issued aMarch 27, 2025 | marketbeat.com19,952 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Proficio Capital Partners LLCProficio Capital Partners LLC purchased a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 19,952 shares of the company's stock, valued at approximately $37March 26, 2025 | marketbeat.comNurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual MeetingMarch 25, 2025 | globenewswire.com Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Media Mentions By Week NRIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRIX News Sentiment▼1.000.72▲Average Medical News Sentiment NRIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRIX Articles This Week▼106▲NRIX Articles Average Week Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News MRUS News MOR News SRRK News PTGX News CRNX News SWTX News OGN News CPRX News VKTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRIX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRIX Stock Free NRIX Stock Alerts